Biography
Carin A. Uyl-de Groot studied Health Care Policy and Management at the Erasmus University Rotterdam. From March 1990 onwards she is working at the institute for Medical Technology Assessment/Department of Health Care Policy and Management at the Erasmus Medical Centre Rotterdam. Her research activities are mainly focused on cost-effectiveness analyses of cancer treatments. Quality of life studies are an integral part of these studies. From 1994 she is program leader of cancer studies. Her main interest consists of diagnostics and therapeutic technologies, economic studies linked to clinical studies, modelling studies, cost studies, quality of life studies, methodological issues and implementation studies particularly in the cancer field. She got her PhD in 1995. Since March 2000 she is director of the institute for Medical Technology Assessment. Since November 2005 she has been appointed professor of health technology assessment at the VU University Medical Center in Amsterdam.
Erasmus School of Health Policy & Management
Full professor | Health Technology Assessment (HTA)
- uyl@eshpm.eur.nl
More information
Work
- N. S.H. Xander, B. Leeneman, A. M.C. Dingemans, W. E. Fiets, W. K. de Jong, N. E.M. Uyl, A. N.M. Wymenga, A. K.L. Reyners & C. A. Uyl-de Groot (2024) - Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not? - European Journal of Cancer, 209 - doi: 10.1016/j.ejca.2024.114262 - [link]
- Leonarda Bremmers, Isabelle Fabbricotti, Leonoor Gräler, Carin de Groot & Leona Hakkaart - van Roijen (2024) - The impact of informal care provision on the quality of life of adults caring for persons with mental health problems: A cross-sectional assessment of caregiver quality of life - Health Psychology Open, 11 - doi: 10.1177/20551029241262883 - [link]
- Sebastiaan N.J. Laan, Suzan de Boer, , Richard J. Dirven, Iris van Moort, Thomas B. Kuipers, Hailiang Mei, Ruben Bierings, Jeroen Eikenboom, Martijn Brands, Sjoerd Koopman, Laura Bukkems, Michael Cloesmeijer, Alexander Janssen, Karin Fijnvandraat, Samantha Gouw, Ron Mathôt, Lotte Haverman, Emile van den Akker, Maartje van den Biggelaar, Masja de Haas, Sander Meijer, Jan Voorberg, Jessica Del Castillo Alferez, Huan Zhang, Johan Boender, Stephan Meijer, Karina Meijer, Sean de Jong, Sebastiaan N.J. Laan, Saskia Schols, Lex Burdorf, Marjon Cnossen, Jan Hazelzet, Elise Huisman, Marieke Kruip, Frank Leebeek, Nikki van Leeuwen, Hester Lingsma, Moniek de Maat, Suzanne Polinder, Simone Reitsma, Ryanne Arisz, Lorenzo Romano, Wala Al Arashi, Shannon van Hoorn, Tine Goedhart, Carin Uyl, Nathalie Jansen, Minka Zivkovic & Annelien Bredenoord (2024) - Transcriptional and functional profiling identifies inflammation and endothelial-to-mesenchymal transition as potential drivers for phenotypic heterogeneity within a cohort of endothelial colony forming cells - Journal of Thrombosis and Haemostasis, 22 (7), 2027-2038 - doi: 10.1016/j.jtha.2024.03.018 - [link]
- Aniek Dane, Carin Uyl-de Groot & Hugo van der Kuy (2024) - Unraveling elements of value-based pricing from a pharmaceutical industry's perspective: a scoping review - Frontiers in Pharmacology, 15 - doi: 10.3389/fphar.2024.1298923 - [link]
- Elaine Julian, Oriol Solà-Morales, Maria João Garcia, Francine Brinkhuis, Mira Pavlovic, Carlos Martín-Saborido, Robin Doeswijk, Rosa Giuliani, Anne Willemsen, Wim Goettsch, Bernhard Wörmann, Urania Dafni, Heiner C. Bucher, Begoña Pérez-Valderrama, Renato Bernardini, Fabrizio Gianfrate, Carin A. Uyl-de Groot & Jörg Ruof (2024) - The Role of Medical Societies and the Relevance of Clinical Perspective in the Evolving EU HTA Process: Insights Generated at the 2023 Fall Convention and Survey of the European Access Academy - Journal of Market Access and Health Policy, 12 (3), 128-143 - doi: 10.3390/jmahp12030011 - [link]
- Renaud J.S.D. Heine, Ron H.J. Mathijssen, Floor A.J. Verbeek, Chantal Van Gils & Carin A. Uyl-de Groot (2024) - Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands - Value in Health, 27 (10), 1367-1372 - doi: 10.1016/j.jval.2024.06.003 - [link]
- Bart Jan Boverhof, W. Ken Redekop, Jacob J. Visser, Carin A. Uyl-de Groot & Maureen P.M.H. Rutten-van Mölken (2024) - Broadening the HTA of medical AI: A review of the literature to inform a tailored approach - Health Policy and Technology, 13 (2) - doi: 10.1016/j.hlpt.2024.100868 - [link]
- Brenda Leeneman, Nicolas S.H. Xander, W. Edward Fiets, Wouter K. de Jong, Nathalie E.M. Uyl, A. N.Machteld Wymenga, An K.L. Reyners & Carin A. Uyl-de Groot (2024) - Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: The impact of different thresholds for effectiveness - European Journal of Cancer, 202 - doi: 10.1016/j.ejca.2024.114002 - [link]
- M. M.J. Galekop, J. Veldwijk, C. A. Uyl-de Groot & W. K. Redekop (2024) - Preferences and willingness to pay for personalized nutrition interventions: Discrete choice experiments in Europe and the United States - Food Quality and Preference, 113 - doi: 10.1016/j.foodqual.2023.105075 - [link]
- Céline van de Braak, François E.J.A. Willemssen, Rob A. de Man, Aad van der Lugt, Carin A. Uyl-de Groot, Daniel Bos & Roy S. Dwarkasing (2024) - Non-contrast short MRI surveillance for HCC screening: the study protocol of the SMS-HCC prospective multicenter study - European radiology experimental, 8 (1) - doi: 10.1186/s41747-024-00432-6 - [link]
- Carin Uyl - de Groot, Ken Redekop, Amir Ansaripour, K. Zendehdel, N. Tadayon & F. Sadeghi (2016) - Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran
Cie Beoordeling Oncologische Middelen
- Start date approval
- juli 2022
- End date approval
- juli 2025
- Place
- UTRECHT
Gezondheidsraad
- Start date approval
- juli 2022
- End date approval
- juli 2025
- Place
- DEN HAAG
bestuurslid CPO, Erasmus Medisch Centrum
- Start date approval
- juli 2022
- End date approval
- juli 2025
- Place
- ONBEKEND
Master Thesis HE
- Year Level
- master, master
Module Knowledge
- Level
- bachelor 1
- Year Level
- bachelor 1
Master Thesis HEPL
- Level
- master
- Year Level
- master
